Lightlake Therapeutics Inc. Set to Begin Phase II Clinical Trials of Binge Eating Disorder Treatment - MarketWatch
Links shared publicly online about this topic.
- 49total visits
Lightlake Therapeutics Inc. Set to Begin Phase II Clinical Trials of Binge Eating Disorder Treatment - MarketWatch
View full resource at marketwatch.com
Tags: Obesity, Eating Disorder, Binge Eating, Nose, Disease and Condition, Clinical Trial
Most Recently Shared on August 24, 2011 at 3:10 pm By:
Nasal spray for the treatment of overweight and obese patients with Binge Eating Disorder? Hmmm http://t.co/emoeoum #RecoveryWarriors
Lightlake to begin opioid antagonist derived nasal spray Phase II trials in Binge Eating Disorder
news-medical.net — “Lightlake Therapeutics Inc., an early stage biopharmaceutical company currently developing a nasal spray for the treatment of overweight and obese patients with Binge Eating Disorder, today announced that its patient testing stage of the Phase II clinical trials will start August 26th, 2011” View full resource at news-medical.net
Most Recently Shared on August 25, 2011 at 6:30 am By:
Lightlake to begin opioid antagonist derived nasal spray Phase II trials in Binge Eating Disorder: Lightlake The... http://t.co/9gQuyJ5
Advertisement
